Latest Transformation News

Core Energy Minerals Ltd has fortified its uranium exploration ambitions with a $3.7 million capital raise and strategic acquisitions in South Australia, setting the stage for a busy 2025 exploration calendar.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for Autosomal Dominant Optic Atrophy, marking a pivotal step in developing a treatment for this currently untreatable blinding disease.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.

Meteoric Resources NL has reported a significant update to its Caldeira Rare Earth Project, highlighting improved financial metrics and exceptional drilling results that reinforce its position as a low-cost rare earths producer.

Nido Education Limited has appointed Adam Lai, former PwC Sydney Managing Partner, as its new CEO starting February 2025, signaling a strategic push for significant expansion over the next five to eight years.

Carnaby Resources has significantly expanded its Greater Duchess Copper Gold Project through the acquisition of the high-grade Trekelano deposit, increasing its Mineral Resource Estimate by 27% and securing a key processing partnership with Glencore.

BetMakers Technology Group reports a sharp 69% reduction in adjusted EBITDA loss and a 43% improvement in operating cash flow for Q2 FY25, marking a pivotal shift from restructuring to growth. The company’s successful Apollo platform migration and cost-cutting initiatives underpin a confident outlook for revenue expansion.

Native Mineral Resources has secured key Queensland gold assets and is advancing refurbishment of the Blackjack Processing Plant, targeting production restart by Q3 2025. The company’s recent capital raises underpin its ambitious development plans.

Gratifii reports a remarkable 110% increase in 2Q FY25 cash receipts, driven by strategic acquisitions and strong client engagement, setting the stage for sustained growth and profitability in the coming quarters.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Simonds Group has agreed to acquire Dennis Family Homes for $10 million, significantly expanding its residential construction footprint and product portfolio across Victoria and New South Wales. The acquisition is expected to be earnings accretive from the first quarter of FY26.

Fluence Corporation Limited delivered a standout Q4 2024 with $21.2 million revenue and $1 million EBITDA, driven by a strategic shift to higher-margin Smart Product Solutions. The company’s robust $88 million backlog and $50 million in new orders set the stage for ambitious growth in 2025.